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Aim To assess the association between renal replacement 
therapy (RRT) and post-transplant infection incidence.
Methods This single-center retrospective cohort study in-
cluded 158 patients who underwent heart transplantation 
(HTx) in our center from 2008 to 2016, survived beyond the 
first post-procedural day, and had available microbial data. 
The patients were dichotomized according to the need for 
periprocedural RRT. Twenty-seven patients in RRT group 
had lower preoperative creatinine clearance, greater body 
mass index, and higher likelihood of having diabetes. Pro-
pensity score adjustment was used to account for multiple 
covariates. The primary outcome measure was the pres-
ence of bacteremia in patients with and without the need 
for RRT. The secondary outcome measures were the pres-
ence of microbial isolates from any culture and clinical out-
come data.
Results Unadjusted analysis showed that the RRT group 
had higher incidence of any positive microbial isolate 
(93% vs 73%; odds ratio [OR] 4.77, 95% confidence inter-
val [CI] 1.01-30.53; P = 0.026) and an increased susceptibil-
ity to bacteremia (50% vs 22%; OR 3.50, 95% CI 1.28-9.67; 
P = 0.012). Propensity score-adjusted analysis corroborated 
the between-group difference in positive blood cultures 
(OR 3.97, 95% CI 1.28-12.32; P = 0.017). There was no differ-
ence in the incidence of total microbial isolates between 
the groups (OR 4.55, 95% CI 0.90-23.05; P = 0.067).
Conclusions Patients requiring RRT after HTx had an in-
creased susceptibility to infections via various portals of 
entry, predominantly due to an increase in blood-borne 
infections. Understanding the underlying conditions lead-
ing to infection-related morbidity is important for infection 
control and prevention.
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Heart failure (HF) definition is a moving target, as new in-
sights into the pathophysiology become available and 
novel markers allow for identification of subclinical HF (1). 
As the projected number of patients with HF increases, so 
does the number of its treatment options. Heart transplan-
tation (HTx) has, however, remained the benchmark with 
which all other therapies are compared (2,3).
Among the most important predictors of adverse out-
comes after HTx are systemic infections (4). The infection 
risk in these patients is promoted by factors such as im-
munosuppression, prolonged use of indwelling cannulas, 
hemodynamic compromise antedating the HTx, and sur-
gical trauma. Additionally, infections are the second most 
common cause of death in patients requiring renal re-
placement therapy (RRT). In these patients, the presence 
of positive microbial isolates carries a significantly worse 
prognosis, irrespective of solid organ transplantation. The 
risk stems from the use of intravascular instrumentation, 
blood product consumption, and disorders of innate and 
adaptive immunity (5).
The unique features of HTx recipients in combination with 
RRT lead to compounding of predisposing conditions for 
infections, with bloodstream infections (BSI) being clear-
ly associated with mortality (4,6,7). Twenty-six percent of 
HTx recipients will develop renal dysfunction within the 
first year (3). Patients requiring RRT therapy after HTx have 
mortality rates exceeding 50% (8). This is in notable con-
trast to the mortality rate in patients who do not develop 
kidney injury (8). Renal insufficiency frequently becomes 
manifest later in the postoperative course as a conse-
quence of prolonged calcineurin-inhibitors use. Sixteen 
percent of patients develop renal dysfunction within five 
years after transplantation and 30% within 10 years after 
transplantation (9).
Understanding the origins and predisposing conditions is 
critical for outcome improvement in patients with post-
transplantation renal dysfunction. The severity of the un-
derlying disease leading to end-organ failure correlates 
with the risk of postoperative morbidity and mortality. 
Similarly, chronic malnutrition and advanced patient age 
predispose to transplantation-associated infections (10).
Most studies on renal dysfunction in cardiac transplant re-
cipients focus on long-term renal outcomes, with only a 
few focusing on the early postoperative period (11,12). The 
impact of renal dysfunction on the infection incidence in 
the early postoperative period remains largely unknown. 
Our aim was to evaluate the association between RRT and 
positive blood cultures in HTx recipients during the first 
postoperative month. We hypothesized that RRT was asso-
ciated with bacteremia and decreased survival.
METHODS
Study participants
This retrospective cohort study was conducted at the Uni-
versity Hospital Center Zagreb in Zagreb, Croatia. One-
hundred and sixty-seven patients underwent HTx in our 
academic center from January 2008 to December 2016. 
The procedures were performed by 6 senior transplant 
surgeons. The inclusion criterion was heart transplantation 
performed during the study period. Exclusion criteria were 
non-transplant cardiac surgical procedures, death within 
the first post-procedural day, and missing microbial data 
(n = 9). The remaining 158 patients were dichotomized ac-
cording to the need for periprocedural RRT (Figure 1). De-
mographic, clinical, and laboratory data were obtained 
from a comprehensive database of HTx patients treated 
in our institution. While RRTs encompass multiple options, 
they all share the goal of fluid removal and solute clear-
ance and are, therefore, presented collectively in our study. 
Patients who did not require RRT postoperatively (non-
RRT group) had significantly different preoperative profiles 
from those who required RRT (RRT group) (Table 1).
To account for these discrepancies and elucidate the inde-
pendent associations between the need for RRT and infec-
tion, we performed a propensity score-adjusted analysis. 
The covariates used in the adjusted analysis included re-
cipient age and sex, organ ischemic time, body mass in-
dex, pulmonary vascular resistance, creatinine clearance, 
duration of cardiopulmonary bypass, diabetes, and pre-
operative and postoperative mechanical circulatory assis-
tance. The primary outcome measure was the presence 
of positive blood cultures within the first postoperative 
month. The secondary outcome measures were the pres-
ence of any microbial isolates within the first postoperative 
month and individual components of this composite out-
come. Furthermore, overall clinical outcomes adjudicated 
at 3 months postoperatively are presented, as is mortality 
among patients with positive blood cultures dichotomized 
with respect to RRT.
The attending microbiologists evaluated all microbiolog-
ical data. Cultures considered to be contaminates were 
excluded from the analysis.
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Heart transplantation
The immunosuppression regime included oral prednisone, 
calcineurin inhibitors (tacrolimus or cyclosporine A [CyA]) 
and mycophenolate mofetil) (13). All patients received in-
duction therapy with antithymocyte globulin. All trans-
plant recipients routinely received antimicrobial prophy-
laxis with vancomycin and meropenem until chest tube 
removal. For oral candidiasis, patients received miconazole 
gel; for Pneumocystis carinii prophylaxis, trimethoprim sul-
famethoxazole; and for cytomegalovirus prophylaxis, gan-
ciclovir followed by valganciclovir (which has improved 
oral bioavailability). The bicaval technique for HTx was 
used in 137 (87%) patients and biatrial HTx in 21 (13%) pa-
tients. All patients received intra-arterial catheters for con-
tinuous systemic blood pressure monitoring as part of 
comprehensive intraoperative monitoring. Furthermore, 
three-luminal central venous catheters were inserted via 
the internal jugular vein and a Swan-Ganz catheter, used 
for continuous pulmonary arterial pressure and intermit-
tent pulmonary capillary wedge pressure monitoring, was 
placed into the pulmonary artery in every patient. Cardiac 
performance was evaluated via thermodilution measure-
ments. All patients underwent intraoperative transesopha-
geal echocardiography.
Microbial culture sampling
All patients were continuously monitored for the presence 
of clinically relevant infections. Patients in whom an infec-
tion was clinically suspected or established were pancul-
tured (paired blood cultures, bronchial aspirates, wound 
discharge cultures [if present], and urine cultures) and un-
derwent appropriate imaging procedures, including chest 
x-rays, computed tomographic imaging, or echocardiogra-
phy. Bronchial aspirates and urine cultures were taken in all 
patients upon arrival to the intensive care unit. Some sam-
ples were subsequently disregarded if they were consid-
ered to be contaminated. Urine cultures are not presented 
because the RRT group had diminished or non-existent 
urine output, which makes the between-group compari-
son impossible. One-hundred and sixteen patients had at 
least one blood culture (90 [69%] in the non-RRT group 
and 26 [96%] in the RRT group). The analysis also included 
FiGurE 1. Study flowchart. *rrT – renal replacement therapy.
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133 bronchial aspiration cultures (106 [81%] in the non-
RRT group and 27 [100%] in the RRT group) and 54 wound 
cultures (43 [33%] in the non-RRT group and 11 [41%] in 
the RRT group).
Statistical analysis
Continuous data are presented as mean ± standard devia-
tion or medians with ranges. Normality of distribution was 
assessed using the Shapiro-Wilk test. The Mann-Whitney U 
test was used for continuous data testing. Categorical vari-
ables and endpoints are presented as absolute numbers 
with percentages and were compared across groups using 
2 × 2 contingency tables. Measures of association were de-
rived from the Fisher exact test. A two-tailed P < 0.05 was 
considered significant. Statistical analysis was performed 
using the Statistica v. 13.0 software package (Dell, Round 




Of 158 HTx recipients, 27 (17%) required RRT. Preoperative 
comorbid factors favoring postoperative RRT requirement 
were higher body mass index, diabetes mellitus, and low-
er preoperative renal reserve (Table 1). Recipient age and 
sex, as well as duration of organ ischemia, cardiopulmo-
nary bypass, and total operative times were comparable 
between the groups. Clinical outcome data are presented 
in Table 2. Sex mismatch between the recipients and the 
donor hearts was present in 49 (31%) of 158 HTx recipi-
ents. It did not influence any of the outcomes. There was 
no difference in the incidence of positive microbial iso-
lates between patients receiving sex-mismatched organs 
and patients receiving sex-matched organs (35/49 [71%] 
vs 85/109 [78%], respectively; P = 0.403). Similarly, the in-
cidences of RRT requirement (7/49 [14%] vs 20/109 [18%], 
respectively; P = 0.689) and 3-month mortality (9/49 [18%] 
vs 13/109 [12%], respectively, P = 0.336) were unaffected by 
sex mismatch.
immunosuppression
Our institutional protocol mandates concentration-con-
trolled mycophenolate mofetil immunosuppression in a 
long-term follow-up but not in the early postoperative 
management. Calcineurin inhibitor immunosuppression 
is, however, dose-controlled as soon as it is started. We 
did not observe a significant difference in the CyA val-
ues between patients who had positive microbial 
TaBLE 1. Preoperative variables in heart transplant recipients dichotomized with respect to renal replacement therapy (rrT)
No. (%) of patients
Patient characteristics rrT group (n = 27) non-rrT group (n = 131) P*
Age (years; median and range)  57 (14-66)  54 (5-70) 0.425
Men  24 (89.0)  96 (73.0) 0.117
Pulmonary vascular resistance (dyn · s · cm−5; mean ± standard deviation) 198 ± 105 209 ± 99 0.371
Body mass index (kg/m2; mean ± standard deviation)  27 ± 3  25 ± 5 0.014
Ischemic cardiomyopathy  13 (48.0)  42 (32.0) 0.124
Dilated cardiomyopathy  13 (48.0)  73 (56.0) 0.579
Diabetes mellitus  11 (41.0)  26 (20.0) 0.026
Hyperlipidemia   7 (26.0)  41 (31.0) 0.701
Preoperative hypertension   9 (33.0)  43 (33.0) 0.998
Chronic obstructive pulmonary disease   1 (4.0)   6 (5.0) 1.0
Atrial fibrillation  10 (37.0)  44 (34.0) 0.789
History of smoking   5 (19.0)  19 (15.0) 0.565
Preoperative beta-blocker  13 (48.0)  64 (49.0) 0.999
Preoperative amiodaron   9 (33.0)  41 (31.0) 0.854
Preoperative aspirin   7 (26.0)  23 (18.0) 0.296
Creatinine clearance (mL/min; mean ± standard deviation)†  53 ± 21  62 ± 21 0.044
Moderate or greater kidney dysfunction  18 (67.0)  61 (47.0) 0.067
Reoperation  10 (37.0)  31 (24.0) 0.156
Preoperative mechanical circulatory support   4 (15.0)  17 (13.0) 0.760
*Mann-Whitney u test was used for continuous variables and the Fisher exact test for categorical variables.
†Defined as creatinine clearance <60 mL/min.
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isolates and those who did not (201 [43-349] ng/mL vs 215 
[150-395] ng/mL, respectively; P = 0.072). Similarly, we did 
not observe a difference in tacrolimus values between pa-
tients who had positive microbial isolates and those who 
did not (13.8 [4.9-27.1] ng/mL vs 11.5 [10.3-13.3] ng/mL, re-
spectively; P = 0.255). Values most proximal to the end of 
the studied postoperative course are presented. We did, 
however, observe significantly higher CyA concentrations 
in patients who did not require RRT (Table 2). Corticoster-
oid levels were not monitored.
Microbial pathogen isolates
The unadjusted univariate analysis showed that the pa-
tients in RRT group were significantly more likely to have 
positive microbial culture isolates from any source and 
from blood cultures in comparison with patients in non-
RRT group (Table 3). Propensity score-adjusted analysis 
corroborated the significant between-group difference 
with respect to positive blood cultures (OR 3.97, 95% CI 
1.28-12.32; P = 0.017), but showed no significant difference 
between the groups with respect to total microbial isolates 
(OR 4.55, 95% CI 0.90-23.05; P = 0.067). No significant dif-
ferences in the proportions of positive microbial cultures 
harvested from the bronchial aspirates and wounds were 
noted between the groups.
There was no difference in the proportion of microbi-
al isolates across the Gram stain spectrum between the 
groups (Table 4). Similarly, the use of oxygen for bacterial 
metabolism did not differ between the groups. The ma-
jority of the isolates belonged to facultative aerobes, es-
pecially in the non-RRT group. None of the comparisons 
in microbial distribution showed a pattern that could be 
related to RRT (Table 4).
TaBLE 3. Primary and secondary study outcomes in univariate analysis of postoperative microbial isolates in heart transplant recipi-
ents dichotomized with respect to renal replacement therapy (rrT)
No. (%) of patients
Primary outcome rrT group non-rrT group Odds ratio (95% confidence interval) P*
No. of patients with positive blood culture† 13/26 (50.0) 20/90 (22.0) 3.50 (1.28-9.67) 0.012
Secondary outcomes
No. of patients with positive microbial isolates‡ 25/27 (93.0) 95/131 (73.0) 4.77 (1.01-30.53) 0.026
No. of patients with positive bronchial aspirate§ 23/27 (85.0) 73/106 (69.0) 2.60 (0.77-9.68) 0.147
No. of patients with positive wound cultureII  8/11 (73.0) 18/43 (42.0) 3.70 (0.74-20.78) 0.095
*Fisher exact test.
†26 patients in the rrT group and 90 patients in the non-rrT group had at least one blood sample cultured.
‡27 patients in the rrT group and 131 patients in the non-rrT group had at least one microbial sample cultured.
§27 patients in the rrT group and 106 patients in the non-rrT group had at least one bronchial aspirate cultured.
ii11 patients in the rrT group and 43 patients in the non-rrT group had at least one wound culture taken.
TaBLE 2. Perioperative variables and clinical outcome data in heart transplant recipients dichotomized with respect to renal replace-
ment therapy (rrT)
No. (%) of patients
Perioperative variables rrT group (n = 27) non-rrT group (n = 131) P*
Organ ischemia (min, mean ± standard deviation) 179 ± 65 183 ± 65 0.801
Cardiopulmonary bypass (min, mean ± standard deviation) 184 ± 78 164 ± 71 0.247
Duration of surgery (min, median and range) 445 (270-780) 420 (190-900) 0.261
recipient-donor sex mismatch   7 (26.0)  42 (32.0) 0.590
Mechanical ventilation (h, median and range)† 252 (24-680)  24 (3-984) <0.001
Postoperative mechanical circulatory support  11 (41.0)   8 (6.0) <0.001
Cyclosporine concentration (ng/mL; median and range) 144 (43-223) 216 (60-395) <0.001
Tacrolimus concentration (ng/mL; median and range)  13.6 (9.2-22.5)  12.7 (4.1-27.1) 0.449
Clinical outcome
Stroke   3 (11.0)   5 (4.0) 0.138
Resternotomy  13 (48.0)  13 (10.0) <0.001
3-month mortality  17 (63.0)   5 (4.0) <0.001
*Mann-Whitney u test was used for continuous variables and the Fisher exact test for categorical variables.
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Clinical outcomes
The incidence of postoperative mechanical circulatory as-
sistance in the RRT group was 41%, compared with only 
6% in the non-RRT group (OR 10.57, 95% CI 3.31-34.54; 
P < 0.001). Patients in the RRT group were also significant-
ly more likely to require prolonged inotropic or vasoactive 
support (Table 5).
The increase in mortality was robust and highly significant 
(17/27 [63%] vs 5/131 [4%], OR 42.84, 95% CI 11.58-170.87; 
P < 0.001). The mortality of patients with positive blood cul-
tures was significantly higher in RRT group than in non-RRT 
group (8/13 [62%] vs 1/20 [5%], OR 30.40, 95% CI 2.58-828.98; 
P = 0.001). Clinical outcome data are summarized in Table 2.
DiSCuSSiON
We showed that RRT following HTx was associated with an 
increased susceptibility to infections via various portals of 
entry, predominantly due to an increase in blood-borne 
infections.
Understanding the underlying conditions leading to infec-
tion-related morbidity is paramount to infection control 
and prevention. Infectious complications remain among 
the leading causes of inferior clinical outcomes in patients 
with solid organ transplantation (14). Bacteremia-associ-
ated annual mortality is 100-300 times greater in RRT pa-
tients compared with the general population irrespective 
of solid organ transplantation (14). Infections after HTx ac-
count for 30% of all deaths within the first postoperative 
year of transplantation (15). This higher infection rate can 
be attributed to both higher immunosuppression levels 
and the temporal proximity to surgical disruption of ana-
tomical barriers (15). Certain predisposing risk factors are 
modifiable, while others are not subject to change. Re-
duction of the immunosuppression dosing may reduce 
infections and mortality incidence, but at the expense of 
increased rejection risk (11). Surgical predisposing factors 
involved are disruption of both allograft vascular supply 
and functional integrity. There is also a clear correlation be-
tween the surgery duration and infection incidence (16).
We specifically examined the impact of RRT on the inci-
dence of new-onset positive microbial isolates from a va-
riety of sampling regions. The observed RRT incidence 
of 17%, which resulted in a 63% mortality rate, is in line 
with previous reports (9). Clearly, kidney dysfunction 
in these patients may only be a measurable metric 
TaBLE 4. Distribution of Gram positive and Gram negative blood culture isolates in heart transplant recipients dichotomized with 
respect to renal replacement therapy (rrT)
No. of blood culture isolates
Microbial isolates rrT group* non-rrT group† P‡
Gram positive  9 (45) 16 (57)   0.559
Gram negative 11 (55) 12 (43)   0.559
Obligate aerobes  4 (20)  2 (7)   0.218
Anaerobes  3 (15)  4 (14) >0.1
Facultative anaerobes 13 (65) 22 (79)   0.339
*20 blood culture isolates from 13 patients.
†28 blood culture isolates from 20 patients.
‡Fisher exact test.
TaBLE 5. Prolonged inotropic support requirement defined as the need for inotropes for 7 or more days in heart transplant recipients 
dichotomized with respect to renal replacement therapy (rrT)
No. (%) of patients
inotrope/ vasoactive medication rrT group (n = 27) non-rrT group (n = 131) P*
Dobutamine  7 (26)  8 (6)   0.005
Epinephrine 15 (56) 18 (14) <0.001
Isoproterenol 17 (63) 68 (52)   0.349
Norepinephrine  8 (30) 16 (12)   0.04
Levosimendan  3 (11)  8 (6)   0.402
Milrinone  3 (11) 25 (19)   0.415
*Fisher exact test.
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of multi-organ failure and not a problem in and of itself. 
Isolated acute renal failure is more likely to occur in pa-
tients with reduced preoperative renal functional reserve 
(17). The interdependent relationship between the heart 
and kidney in HTx candidates is invariably compromised. 
The ensuing cardiorenal syndrome results in chronic kid-
ney disease, which was common in our patient popula-
tion. An additional attribute of the HTx population requir-
ing RRT was that the optimization of their hemodynamics 
required prolonged inotropic support. This underscores 
their inherent postoperative hemodynamic compromise, 
which, coupled with the prolonged use of intravascular 
instrumentation required for RRT and drug delivery, likely 
enhanced the susceptibility to infections. We found higher 
CyA levels in patients who did not require RRT, likely due to 
the fact that CyA doses were purposefully reduced in pa-
tients with signs of acute kidney injury in order to reduce 
the nephrotoxic impact of CyA.
The focus of our study was on bacterial microbial isolates 
since these infections predominate in the immediate pe-
rioperative period, as opposed to viral, opportunistic, and 
fungal infections, which predominate later on.
In a Spanish study from the RESITRA cohort, the BSI inci-
dence in HTx recipients was 11% (4). Rodriguez et al (16) 
reported 60 BSI episodes in 15.8% of patients in the post-
operative period. It is important to note that over 50% of 
all bacterial infections occur within the first postoperative 
month (8). We performed microbiological surveillance 
sampling systematically, irrespective of clinical indications, 
as a part of our standard institutional protocol. Therefore, 
not all positive microbial culture isolates resulted in clini-
cally relevant infections.
Bacteremia is most commonly associated with vascular ac-
cess and especially with central venous catheters use, with 
32% of hospitalizations for vascular access infection oc-
curring in patients with a central venous catheter in place 
(5). Most patients develop at least one serious periproce-
dural complication (serious infection, cardiac morbidity, or 
neurological morbidity) before requiring RRT. In contrast, 
only 17% of patients develop severe renal injury requir-
ing RRT without adjoining non-renal comorbidities, which 
is consistent with our results. Only one previous study 
identified RRT to be an independent risk factor for bac-
teremia in HTx patients (16). The authors concluded that 
immune alterations produced by renal failure and sub-
sequent RRT were responsible for the increased risk of 
adverse outcomes. Independent risk factors for BSI 
were prolonged intensive care unit stay and previous cy-
tomegalovirus infection (16). In liver and kidney transplant 
patients, bacteremia is a predictor of higher mortality up 
to two months after transplantation (16). Regional bacte-
rial epidemiology should be closely followed and appreci-
ated in order to design the appropriate antibiotic prophy-
laxis for solid organ transplantation
A limitation of our study is bias in data selection and anal-
ysis stemming from the study’s retrospective design. An-
other limitation is incompleteness of data input, leading 
to possible underappreciation of some confounding vari-
ables. Patients experiencing a complicated postoperative 
course will have a proportionally greater need for a vari-
ety of diagnostic and therapeutic procedures (analysis of 
microbiological samples included). This could enhance 
the probability of diagnosing an incipient microbial isolate 
in the RRT group, which would have otherwise not been 
identified had the postoperative course been uneventful.
In conclusion, we found that patients requiring RRT had 
markedly more complicated postoperative courses. We 
also documented a significant relationship between RRT 
and an increased infection risk. Our data add to the litera-
ture on the subject of early post-transplantation infection 
burden. Measures designed to reduce the bacteremia in-
cidence should be rigorously implemented in heart trans-
plant recipients, and especially in patients with increased 
susceptibility to renal failure.
Oxford Centre for Evidence-based Medicine level of evidence: 3b.
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